Abstract
While bodyweight reduction should be a primary intervention target in obese heart failure with preserved ejection fraction (HFpEF) patients, no pharmacological treatments have shown evidence. The STEP HFpEF trial1 showed that semaglutide significantly improved various aspects of heart failure-related clinical outcomes in obese HFpEF patients, along with remarkable weight loss.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
